Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥20 years of age~2. Histologically or cytologically confirmed unresectable, recurrent or metastatic gastric cancer~3. Failure of a first line therapy with fluoropyrimidine +/- platinum for metastatic or recurrent disease.(Adjuvant chemotherapy is not considered as a first line chemotherapy unless recurrence developed within 6 months of completion of adjuvant therapy.)~4. Adequate bone marrow, liver and renal functions~5. INR ≤ 2.0~6. ECOG performance status ≤ 2~7. Neuropathy grade ≤ 1~8. Life expectancy of at least 3 months~9. Measurable lesion according to RECIST version 1.1 on CT scan~10. Written informed consent~11. Patients of child bearing age have to agree to the usage of adequate contraception from before the registration to the study, during the participation period and 90 days after the end of treatment. Female of child bearing age has to show negative for urin pregnancy test within 7 days from beginning of the start of administration. Amenorrhea status has to be sustained for at least 12 months to be considered non-pregnant in case of postmenstrual women.~Exclusion Criteria:~1. Major infectious disease, neurological disorder, or bowel obstruction.~2. Patients with CNS metastases(confirmed through brain imaging if there are symptoms)~3. Patient diagnosed with another cancer type (except non-melanoma skin cancer, cervical cancer, or any other cancer that did not recur or metastasized for more than 5 years and considered as complete remission can be registered)~4. Patient who received radiation therapy within past 2 weeks or who had major surgery including organ resection within past 4 weeks from random assignment date~5. Patient with the history of failure to the taxane chemotherapy~6. Patient who need chronic concomitant use of P glycoprotein, immune suppressor, proton pump inhibitor, or H2-receptor antagonist during the period of clinical trial~7. Chronic treatment using steroid (except oral, local injection, or for externally applied) or other immune suppressor~8. Patient with myocardial infarction, congestive heart failure, arrhythmia showing abrupt change in the ECG, severe or unstable angina, or other serious heart disease~9. Patient with other serious internal disease (chronic obstructive or chronic inhibitory lung disease including shortness of breathe at rest due to all reasons, uncontrollable diabetes and hypertension)~10. History of abuse of a drug or alcohol within 3 months~11. Lactating or pregnant women, or patient (or spouse) who has no intension of using, or cannot use very effective mean of contraception~12. Patient who has or is suspected to have problem in bile acid secretion~13. Patient with active gastrointestinal bleeding, or taking oral anti- vitamine K (With the exception of low dose of Warfarin and acetylsalicylic acide when INR≤2.0)~14. History of serious hypersensitive reaction to the main ingredient or the excipient of the investigational drug~15. History of being seropositive for HIV (HIV test is not a prerequisite).~16. Patients with gastrointestinal dysfunction or on enteral feeding~17. Other patients who are deemed inadequate to participate in the clinical trial by the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHP107 (oral paclitaxel) (Type: EXPERIMENTAL): DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
- Taxol® (IV paclitaxel) (Type: ACTIVE_COMPARATOR): Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.

Based on this trial design, predict the completion outcome and termination type (if applicable).